BioSyent Gains Health Canada Approval for Thyconvi as Canada's First Oral Liquid Levothyroxine

A formulation gap in Canadian hypothyroidism management closes with Health Canada's approval of BioSyent's Thyconvi™ (levothyroxine sodium oral solution), the first liquid levothyroxine dosage form authorized in the country. For regulatory and formulation teams pursuing liquid dosage form approvals, the clearance signals that Health Canada will evaluate novel delivery formats in well-established therapeutic classes where unmet clinical need can be demonstrated.

Thyconvi™ is supplied as a 20 mcg/mL oral solution, packaged in two 75 mL bottles with no refrigeration requirement. The approved indications span primary, secondary, and tertiary hypothyroidism across all patient ages and states, including pregnancy, and extend to pituitary TSH suppression as an adjunct to surgery and radioiodine therapy in well-differentiated thyroid carcinoma. The ambient storage condition and broad indication label reflect formulation and stability work that QA teams at liquid-dosage facilities will recognize as non-trivial for a narrow-therapeutic-index hormone product.

BioSyent Pharma Inc., a wholly owned subsidiary holding the exclusive Canadian licence to register, market, and distribute Thyconvi™, has not disclosed a commercial launch date beyond "coming months." The clinical rationale centres on consistent day-to-day dosing and titration flexibility in patient populations where solid oral formulations present compliance or swallowing challenges, a positioning that regulatory affairs leads will note was sufficient to support a distinct product authorization rather than a line extension under an existing tablet NDS.

For QA directors at contract liquid manufacturing sites, the approval is a reference point: a narrow-therapeutic-index oral solution cleared under Canadian regulatory standards without a cold-chain requirement, which carries implications for comparability assessments and process validation protocols on similar programs. Dose accuracy and container-closure integrity will remain the critical quality attributes under scrutiny at any pre-approval inspection for analogous submissions.

The commercial launch timeline, once confirmed, will set the clock on post-market commitments and any risk management program obligations BioSyent carries forward under the approval conditions.

Source: BioSyent Inc. via GlobeNewswire, May 19, 2026.